Fig. 5

Effects of immunodepletion on amyloid-β (Aβ) levels in brain extracts. The percentage change of Aβ40 (grey) and Aβ42 (black) concentration to pre-immunodepleted (pre-IP) conditions (set to 100%) for A controls and B AD patients separately or C combined. Bar graphs show the mean ± SD, data points represent the individual values for control and/or AD patient brain extracts. Shapiro-Wilk normality testing was followed by parametric (ordinary) or non-parametric (Kruskall-Wallis) one-way ANOVA, and groups were compared to IgG3 control. Statistical testing confirmed that Aβ40/42 values did not differ between IgG3 control and pre-immunodepleted conditions. Note that Aβ42 levels were above the detection limit after 4G8 treatment for only one control case, resulting in a non-significant statistical difference due to an n=1 sample size. In the IgG3 condition in C, one outlier was detected and removed for subsequent analysis. Significance values are shown in the graph, ns = not significant